These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 24224693)

  • 21. Synthesis and biological evaluation of new N-alkyl 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides as cannabinoid receptor ligands.
    Silvestri R; Ligresti A; La Regina G; Piscitelli F; Gatti V; Lavecchia A; Brizzi A; Pasquini S; Allarà M; Fantini N; Carai MA; Bigogno C; Rozio MG; Sinisi R; Novellino E; Colombo G; Di Marzo V; Dondio G; Corelli F
    Eur J Med Chem; 2010 Dec; 45(12):5878-86. PubMed ID: 20943290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SLV330, a cannabinoid CB1 receptor antagonist, ameliorates deficits in the T-maze, object recognition and Social Recognition Tasks in rodents.
    de Bruin NM; Prickaerts J; Lange JH; Akkerman S; Andriambeloson E; de Haan M; Wijnen J; van Drimmelen M; Hissink E; Heijink L; Kruse CG
    Neurobiol Learn Mem; 2010 May; 93(4):522-31. PubMed ID: 20132903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peripherally restricted CB1 receptor blockers.
    Chorvat RJ
    Bioorg Med Chem Lett; 2013 Sep; 23(17):4751-60. PubMed ID: 23902803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A selective cannabinoid-1 receptor antagonist, PF-95453, reduces body weight and body fat to a greater extent than pair-fed controls in obese monkeys.
    Wagner JD; Zhang L; Kavanagh K; Ward GM; Chin JE; Hadcock JR; Auerbach BJ; Harwood HJ
    J Pharmacol Exp Ther; 2010 Oct; 335(1):103-13. PubMed ID: 20605903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.
    Shearman LP; Stribling DS; Camacho RE; Rosko KM; Wang J; Tong S; Feng Y; Marsh DJ; Yu H; Guan X; Spann SK; Macneil DJ; Fong TM; Metzger JM; Goulet MT; Hagmann WK; Plummer CW; Finke PE; Mills SG; Shah SK; Truong Q; Van der Ploeg LH; Macintyre DE; Strack AM
    Eur J Pharmacol; 2008 Jan; 579(1-3):215-24. PubMed ID: 18021763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a peripherally restricted cannabinoid CB1/CB2 receptor agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice.
    Cluny NL; Keenan CM; Duncan M; Fox A; Lutz B; Sharkey KA
    J Pharmacol Exp Ther; 2010 Sep; 334(3):973-80. PubMed ID: 20571060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pentacycle derivatives as cannabinoid CB1 receptor ligands.
    Lee SH; Seo HJ; Kim MJ; Kang SY; Lee SH; Ahn K; Lee M; Han HK; Kim J; Lee J
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6632-6. PubMed ID: 19850473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of fatty acid oxidation resists weight gain, ameliorates hepatic steatosis and reduces cardiometabolic risk factors.
    Vijayakumar RS; Lin Y; Shia KS; Yeh YN; Hsieh WP; Hsiao WC; Chang CP; Chao YS; Hung MS
    Int J Obes (Lond); 2012 Jul; 36(7):999-1006. PubMed ID: 21894162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity.
    Dow RL; Carpino PA; Hadcock JR; Black SC; Iredale PA; DaSilva-Jardine P; Schneider SR; Paight ES; Griffith DA; Scott DO; O'Connor RE; Nduaka CI
    J Med Chem; 2009 May; 52(9):2652-5. PubMed ID: 19351113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.
    Lee J; Seo HJ; Lee SH; Kim J; Jung ME; Lee SH; Song KS; Lee J; Kang SY; Kim MJ; Kim MS; Son EJ; Lee M; Han HK
    Bioorg Med Chem; 2010 Sep; 18(17):6377-88. PubMed ID: 20673729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice.
    Hildebrandt AL; Kelly-Sullivan DM; Black SC
    Eur J Pharmacol; 2003 Feb; 462(1-3):125-32. PubMed ID: 12591104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of Oxygen-Bridged Pyrazole-Based Structures as Cannabinoid Receptor 1 Ligands.
    Murineddu G; Asproni B; Corona P; Piras S; Lazzari P; Ruiu S; Legnani L; Toma L; Pinna GA
    Molecules; 2019 Apr; 24(9):. PubMed ID: 31035548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and structure-activity relationship of 1,2,4-triazole-containing diarylpyrazolyl carboxamide as CB1 cannabinoid receptor-ligand.
    Seo HJ; Kim MJ; Lee SH; Lee SH; Jung ME; Kim MS; Ahn K; Kim J; Lee J
    Bioorg Med Chem; 2010 Feb; 18(3):1149-62. PubMed ID: 20045337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesity.
    Hadcock JR; Griffith DA; Iredale PA; Carpino PA; Dow RL; Black SC; O'Connor R; Gautreau D; Lizano JS; Ward K; Hargrove DM; Kelly-Sullivan D; Scott DO
    Biochem Biophys Res Commun; 2010 Apr; 394(2):366-71. PubMed ID: 20211605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice.
    Jin K; Xie L; Kim SH; Parmentier-Batteur S; Sun Y; Mao XO; Childs J; Greenberg DA
    Mol Pharmacol; 2004 Aug; 66(2):204-8. PubMed ID: 15266010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel thioamide derivatives as neutral CB1 receptor antagonists.
    Boström J; Olsson RI; Tholander J; Greasley PJ; Ryberg E; Nordberg H; Hjorth S; Cheng L
    Bioorg Med Chem Lett; 2010 Jan; 20(2):479-82. PubMed ID: 20005704
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling.
    Patel S; Hillard CJ
    J Pharmacol Exp Ther; 2006 Jul; 318(1):304-11. PubMed ID: 16569753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis, cannabinoid receptor affinity, and molecular modeling studies of substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides.
    Silvestri R; Cascio MG; La Regina G; Piscitelli F; Lavecchia A; Brizzi A; Pasquini S; Botta M; Novellino E; Di Marzo V; Corelli F
    J Med Chem; 2008 Mar; 51(6):1560-76. PubMed ID: 18293908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diaryl dihydropyrazole-3-carboxamides with significant in vivo antiobesity activity related to CB1 receptor antagonism: synthesis, biological evaluation, and molecular modeling in the homology model.
    Srivastava BK; Joharapurkar A; Raval S; Patel JZ; Soni R; Raval P; Gite A; Goswami A; Sadhwani N; Gandhi N; Patel H; Mishra B; Solanki M; Pandey B; Jain MR; Patel PR
    J Med Chem; 2007 Nov; 50(24):5951-66. PubMed ID: 17979261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis, Biological Evaluation, and Molecular Modeling Studies of 3,4-Diarylpyrazoline Series of Compounds as Potent, Nonbrain Penetrant Antagonists of Cannabinoid-1 (CB
    Iyer MR; Cinar R; Wood CM; Zawatsky CN; Coffey NJ; Kim KA; Liu Z; Katz A; Abdalla J; Hassan SA; Lee YS
    J Med Chem; 2022 Feb; 65(3):2374-2387. PubMed ID: 35084860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.